<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083680</url>
  </required_header>
  <id_info>
    <org_study_id>P10-278</org_study_id>
    <nct_id>NCT01083680</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine</brief_title>
  <official_title>Post-marketing Observational Study to Evaluate the Safety and Efficacy of HUMIRA® (Adalimumab SC) for the Treatment of Moderate to Severe Crohn's Disease in Daily Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was intended to evaluate the long-term safety and effectiveness of
      adalimumab in participants with Crohn's disease (CD) who are treated as recommended in the
      product label.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a 60-month prospective, multicenter, observational study of adalimumab in
      adult participants with CD who resided in Germany. Visits were scheduled every 3 months for
      the first year and every 6 months thereafter. Participants continued in the study for a
      maximum of 60 months or until discontinuation from adalimumab therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) at Each Visit</measure>
    <time_frame>Months 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
    <description>The CDAI is a measure of clinical response and remission that was developed for use in clinical trials. The CDAI includes 8 variables encompassing both patient-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, patients keep track of daily symptoms on a diary card, and the daily symptom scores are summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 would the lower limit with no set upper limit. The scale for the scores is as follows: &lt; 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and &gt; 450 to define severely active disease. Negative changes indicate reductions (improvement) in disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Full Analysis Set (FAS) Participants in Each CDAI Disease Classification Over Time</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
    <description>The CDAI is a measure of clinical response and remission that was developed for use in clinical trials. The CDAI includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, patients keep track of daily symptoms on a diary card, and the daily symptom scores are summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; there is no set upper limit. The scale for the scores is as follows: &lt; 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and &gt; 450 to define severely active disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) at Each Visit in FAS Participants</measure>
    <time_frame>Months 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
    <description>The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is an abbreviated version of the Inflammatory Bowel Disease (IBD) Questionnaire, a Health-related quality of life (HRQOL) assessment tool for patients with IBD. The SIBDQ utilizes 10 items concerning patient well-being during the last 2 weeks, each of which is scored on a scale of 1 (poor HRQOL) to 7 (optimum HRQOL). The individual sub scores are added to produce the total SIBDQ score. SIBDQ scores range from 10 to 70 with higher values indicating better HRQOL. Positive changes indicate reductions in disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (Excluding Serious Adverse Events)</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not the event is considered causally related to the use of the product.
For more details on adverse events please see the AE section below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>4.Mean Harvey Bradshaw Index (HBI) in Full Analysis Set (FAS) Participants Over Time</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
    <description>The HBI is a simplified version of the CDAI; HBI scores correlate well with CDAI scores. The HBI consists of 5 items encompassing patient-reported (well-being, symptoms)and objective (presence of abdominal mass or complications) variables. Symptom scores are based on symptom status on the previous day rather than the total of 7 days as for the CDAI. The total HBI score is the sum of the values for each of the five items. Higher HBI scores indicate greater disease activity; 0 would the lower limit with no set upper limit. Scores &lt; 5 indicate remission, 5 - 7 indicate mild disease, 8 - 16 indicate moderate disease, and 16 indicate severe disease. Each HBI unit is equivalent to approximately 27 CDAI units. Higher scores indicate greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance With the Self-injection Via the Humira®-PEN</measure>
    <time_frame>Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
    <description>Adalimumab will be self-administered by participants using Humira®-PEN. Analysis of compliance was not performed as outlined in the protocol.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4107</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Participants with Crohn's Disease (CD)</arm_group_label>
    <description>Participants with Crohn's Disease treated with adalimumab (HUMIRA®) in routine clinical practice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study population consisted of participants with Crohn's Disease (CD) who were treated with
        adalimumab.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Severe, active Crohn's Disease in patients with insufficient response to a complete and
        adequate therapy of glucocorticoid and/or immunosuppressive drug and/or hypersensitivity
        against such a therapy or in patients where such a therapy is contraindicated.

        Exclusion Criteria:

        - Hypersensitivity against the drug or one of the other ingredients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Bloch, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Deutschland GmbH &amp; Co. KG, Medical Department</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>December 13, 2016</results_first_submitted>
  <results_first_submitted_qc>March 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Routine clinical setting</keyword>
  <keyword>Long-term efficacy and safety</keyword>
  <keyword>Crohn's Disease</keyword>
  <keyword>Humira®</keyword>
  <keyword>Adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 4107 participants were enrolled: 1621 in the full analysis set (FAS) population were analyzed for efficacy; 4107 were analyzed for safety.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Participants With Crohn's Disease (CD)</title>
          <description>Participants with Crohn's Disease treated with adalimumab in routine clinical practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS), Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1621"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3844"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2758"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1086"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analyses accounts for safety analysis set population (all participants who received at least 1 dose of study drug).</population>
      <group_list>
        <group group_id="B1">
          <title>Participants With Crohn's Disease (CD)</title>
          <description>Participants with Crohn's Disease treated with adalimumab in routine clinical practice.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Baseline analysis (age, continuous) accounts for safety analysis set population with available data. This information wasn't available for 31 participants.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4076"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Baseline analysis (gender) accounts for safety analysis set population with available data. This information wasn't available for 24 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4083"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2500"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) at Each Visit</title>
        <description>The CDAI is a measure of clinical response and remission that was developed for use in clinical trials. The CDAI includes 8 variables encompassing both patient-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, patients keep track of daily symptoms on a diary card, and the daily symptom scores are summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 would the lower limit with no set upper limit. The scale for the scores is as follows: &lt; 150 to indicate remission, 150 – 219 to define mildly active disease, 220 – 450 to define moderately active disease, and &gt; 450 to define severely active disease. Negative changes indicate reductions (improvement) in disease activity.</description>
        <time_frame>Months 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
        <population>Effectiveness analyses included all participants with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Crohn's Disease (CD)</title>
            <description>Participants with Crohn's Disease treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) at Each Visit</title>
          <description>The CDAI is a measure of clinical response and remission that was developed for use in clinical trials. The CDAI includes 8 variables encompassing both patient-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, patients keep track of daily symptoms on a diary card, and the daily symptom scores are summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 would the lower limit with no set upper limit. The scale for the scores is as follows: &lt; 150 to indicate remission, 150 – 219 to define mildly active disease, 220 – 450 to define moderately active disease, and &gt; 450 to define severely active disease. Negative changes indicate reductions (improvement) in disease activity.</description>
          <population>Effectiveness analyses included all participants with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-117" spread="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="992"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-124" spread="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="832"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-131" spread="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="734"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-137" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="620"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-142" spread="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-137" spread="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-145" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-149" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-151" spread="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-153" spread="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-156" spread="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-138" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Full Analysis Set (FAS) Participants in Each CDAI Disease Classification Over Time</title>
        <description>The CDAI is a measure of clinical response and remission that was developed for use in clinical trials. The CDAI includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, patients keep track of daily symptoms on a diary card, and the daily symptom scores are summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; there is no set upper limit. The scale for the scores is as follows: &lt; 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and &gt; 450 to define severely active disease.</description>
        <time_frame>Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
        <population>Effectiveness analyses included all participants with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Crohn's Disease (CD)</title>
            <description>Participants with Crohn's Disease treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Full Analysis Set (FAS) Participants in Each CDAI Disease Classification Over Time</title>
          <description>The CDAI is a measure of clinical response and remission that was developed for use in clinical trials. The CDAI includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, patients keep track of daily symptoms on a diary card, and the daily symptom scores are summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; there is no set upper limit. The scale for the scores is as follows: &lt; 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and &gt; 450 to define severely active disease.</description>
          <population>Effectiveness analyses included all participants with evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1471"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 0 (Mild disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 0 (Moderate disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 0 (Severe disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (Mild disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1066"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1066"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1066"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1066"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="880"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="880"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="880"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="880"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="665"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (Mild disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="665"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="665"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="665"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="536"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="536"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="536"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="536"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (Severe Diease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 54 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 54 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 54 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 54 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (Remission)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (Mild Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (Moderate Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (Severe Disease)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) at Each Visit in FAS Participants</title>
        <description>The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is an abbreviated version of the Inflammatory Bowel Disease (IBD) Questionnaire, a Health-related quality of life (HRQOL) assessment tool for patients with IBD. The SIBDQ utilizes 10 items concerning patient well-being during the last 2 weeks, each of which is scored on a scale of 1 (poor HRQOL) to 7 (optimum HRQOL). The individual sub scores are added to produce the total SIBDQ score. SIBDQ scores range from 10 to 70 with higher values indicating better HRQOL. Positive changes indicate reductions in disease activity.</description>
        <time_frame>Months 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
        <population>Effectiveness analyses included all participants with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Crohn's Disease (CD)</title>
            <description>Participants with Crohn's Disease treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) at Each Visit in FAS Participants</title>
          <description>The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is an abbreviated version of the Inflammatory Bowel Disease (IBD) Questionnaire, a Health-related quality of life (HRQOL) assessment tool for patients with IBD. The SIBDQ utilizes 10 items concerning patient well-being during the last 2 weeks, each of which is scored on a scale of 1 (poor HRQOL) to 7 (optimum HRQOL). The individual sub scores are added to produce the total SIBDQ score. SIBDQ scores range from 10 to 70 with higher values indicating better HRQOL. Positive changes indicate reductions in disease activity.</description>
          <population>Effectiveness analyses included all participants with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="947"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="947"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="790"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="576"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="486"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events (Excluding Serious Adverse Events)</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not the event is considered causally related to the use of the product.
For more details on adverse events please see the AE section below.</description>
        <time_frame>Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
        <population>Analysis included safety analysis population with incidence of greater than 1% during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Crohn's Disease (CD)</title>
            <description>Participants with Crohn's Disease treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (Excluding Serious Adverse Events)</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not the event is considered causally related to the use of the product.
For more details on adverse events please see the AE section below.</description>
          <population>Analysis included safety analysis population with incidence of greater than 1% during the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4.Mean Harvey Bradshaw Index (HBI) in Full Analysis Set (FAS) Participants Over Time</title>
        <description>The HBI is a simplified version of the CDAI; HBI scores correlate well with CDAI scores. The HBI consists of 5 items encompassing patient-reported (well-being, symptoms)and objective (presence of abdominal mass or complications) variables. Symptom scores are based on symptom status on the previous day rather than the total of 7 days as for the CDAI. The total HBI score is the sum of the values for each of the five items. Higher HBI scores indicate greater disease activity; 0 would the lower limit with no set upper limit. Scores &lt; 5 indicate remission, 5 – 7 indicate mild disease, 8 – 16 indicate moderate disease, and 16 indicate severe disease. Each HBI unit is equivalent to approximately 27 CDAI units. Higher scores indicate greater disease activity.</description>
        <time_frame>Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
        <population>Effectiveness analyses included all participants with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Crohn's Disease (CD)</title>
            <description>Participants with Crohn's Disease treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>4.Mean Harvey Bradshaw Index (HBI) in Full Analysis Set (FAS) Participants Over Time</title>
          <description>The HBI is a simplified version of the CDAI; HBI scores correlate well with CDAI scores. The HBI consists of 5 items encompassing patient-reported (well-being, symptoms)and objective (presence of abdominal mass or complications) variables. Symptom scores are based on symptom status on the previous day rather than the total of 7 days as for the CDAI. The total HBI score is the sum of the values for each of the five items. Higher HBI scores indicate greater disease activity; 0 would the lower limit with no set upper limit. Scores &lt; 5 indicate remission, 5 – 7 indicate mild disease, 8 – 16 indicate moderate disease, and 16 indicate severe disease. Each HBI unit is equivalent to approximately 27 CDAI units. Higher scores indicate greater disease activity.</description>
          <population>Effectiveness analyses included all participants with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1621"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1097"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="977"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="817"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance With the Self-injection Via the Humira®-PEN</title>
        <description>Adalimumab will be self-administered by participants using Humira®-PEN. Analysis of compliance was not performed as outlined in the protocol.</description>
        <time_frame>Months 0, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60</time_frame>
        <population>Compliance data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Crohn's Disease (CD)</title>
            <description>Participants with Crohn's Disease treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With the Self-injection Via the Humira®-PEN</title>
          <description>Adalimumab will be self-administered by participants using Humira®-PEN. Analysis of compliance was not performed as outlined in the protocol.</description>
          <population>Compliance data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from start of study (month 0) through month 60 following the start of treatment with adalimumab.</time_frame>
      <desc>Analysis included safety analysis population i.e., all participants who received at least 1 dose of adalimumab with evaluable safety data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Participants With Crohn's Disease (CD)</title>
          <description>Participants with Crohn's Disease treated with adalimumab in routine clinical practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="548" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>PYLORIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>INNER EAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SUDDEN HEARING LOSS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TYMPANIC MEMBRANE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>SECONDARY ADRENOCORTICAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ULCERATIVE KERATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>UVEITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABDOMINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANAL SKIN TAGS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BARRETT'S OESOPHAGUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CHRONIC GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>COLONIC FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DUODENAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DUODENAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ENTEROCOLONIC FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ENTEROCUTANEOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>EPIGASTRIC DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTRIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL WALL THICKENING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ILEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL DILATATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL SCARRING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>JEJUNAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LOCALISED INTRAABDOMINAL FLUID COLLECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MECHANICAL ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OBSTRUCTION GASTRIC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PAINFUL DEFAECATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RECTAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>VOLVULUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE EVENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>EMBOLIA CUTIS MEDICAMENTOSA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FEELING HOT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS SCLEROSING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GALLBLADDER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GALLBLADDER POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HEPATITIS CHOLESTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HYDROCHOLECYSTIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO ANIMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SERUM SICKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABSCESS INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABSCESS JAW</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANGULAR CHEILITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BARTHOLIN'S ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BREAST ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CENTRAL NERVOUS SYSTEM VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CHRONIC SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DIARRHOEA INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DISSEMINATED TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ECZEMA INFECTED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GONORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HAEMATOMA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HELICOBACTER GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INFECTED FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MENINGOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OPPORTUNISTIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PERITONEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PERITONITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PERIUMBILICAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RENAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TONSILLITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TUBO-OVARIAN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>VULVAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ACCIDENT AT WORK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL ANASTOMOSIS COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PROCEDURAL INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>STOMA COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>STOMAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>COLONOSCOPY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DIAGNOSTIC PROCEDURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>EMERGENCY CARE EXAMINATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ENDOSCOPY SMALL INTESTINE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ENDOSCOPY UPPER GASTROINTESTINAL TRACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ENTEROCLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LAPAROSCOPY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>NUCLEAR MAGNETIC RESONANCE IMAGING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OESOPHAGOGASTRODUODENOSCOPY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RENAL FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>CACHEXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ARTHRITIS ENTEROPATHIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ENTHESOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LUPUS-LIKE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MUSCLE TWITCHING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PERIOSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SACROILIITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SPONDYLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADENOCARCINOMA OF COLON</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANAPLASTIC ASTROCYTOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANOGENITAL WARTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BURKITT'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>COLORECTAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FOLLICULAR DENDRITIC CELL SARCOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STROMAL TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HODGKIN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HODGKIN'S DISEASE STAGE II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PHAEOCHROMOCYTOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SARCOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SEMINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AUTONOMIC NERVOUS SYSTEM IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BASAL GANGLIA INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BRAIN OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CENTRAL NERVOUS SYSTEM INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL VENOUS SINUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SIMPLE PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABORTION EARLY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DELIVERY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ACUTE PRERENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BLADDER NECK OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CALCULUS BLADDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>URETERIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>URETEROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>UROGENITAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>VESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CERVICAL DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ERECTILE DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FEMALE GENITAL TRACT FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>VAGINAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DEVIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>NASAL TURBINATE HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DERMATITIS PSORIASIFORM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ERYTHEMA NODOSUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HIDRADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>NEURODERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PUSTULAR PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RASH GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ROSACEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SKIN FISSURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>INADEQUATE DIET</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABSCESS DRAINAGE</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ADHESIOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANOPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ANORECTAL OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>APPENDICECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BLADDER CATHETERISATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>BREAST CONSERVING SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CAESAREAN SECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CANCER SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>COLECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>COLECTOMY TOTAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>COLORECTOSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>COLOSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DEBRIDEMENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ENTEROSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>FISTULA REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GALLBLADDER OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DILATION PROCEDURE</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HOSPITALISATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ILEECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ILEOCOLOSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>ILEOSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL ANASTOMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL FISTULA REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>INTESTINAL RESECTION</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>JEJUNECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>JEJUNOSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>LIPOMA EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MAMMOPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>MASS EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>NASAL SEPTAL OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>OVARIAN CYSTECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PROCTECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PROCTOCOLECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>PYLORUS DILATION PROCEDURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RECTAL FISTULA REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>RESUSCITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SHOULDER OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SIGMOIDECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SKIN NEOPLASM EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL RESECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>STRICTUROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>THYROID ADENOMA REMOVAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TOOTH EXTRACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TRANSFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TUMOUR EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>TYMPANOPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>URETERIC OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>URINARY TRACT OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>VAGINOPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>WOUND TREATMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Information</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

